Evidence map›Paper›PMID 42155729›Full record

ArticleMolecular & cellular proteomics : MCP2026

A Platform for High-throughput and Ultrasensitive Immunopeptidomics.

Adillah Gul, Laura Van Moortel, Patrick Willems, Ilke Aernout, Laura Pedró-Cos, Kia C Ferrell, Katie Boucher, An Staes, Simon Devos, Ine Lentacker and 4 more

Abstract read
In one paragraph

Article in Molecular & cellular proteomics : MCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Adillah GulVIB Center for Medical Biotechnology, VIB, Ghent, Belgium; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.
Laura Van MoortelVIB Center for Medical Biotechnology, VIB, Ghent, Belgium; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.
Patrick WillemsVIB Center for Medical Biotechnology, VIB, Ghent, Belgium; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.
Ilke AernoutGhent Research Group on Nanomedicines, Ghent University, Ghent, Belgium; Cancer Research Institute Ghent (CRIG), Ghent, Belgium.
Laura Pedró-CosInstitut Pasteur, Université Paris Cité, Inserm U1224, Immunobiology and Therapy Unit, Paris, France.
Kia C FerrellInstitut Pasteur, Université Paris Cité, Inserm U1224, Immunobiology and Therapy Unit, Paris, France.
Katie BoucherVIB Center for Medical Biotechnology, VIB, Ghent, Belgium; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium; VIB Proteomics Core, VIB, Ghent, Belgium.
An StaesVIB Center for Medical Biotechnology, VIB, Ghent, Belgium; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium; VIB Proteomics Core, VIB, Ghent, Belgium.
Simon DevosVIB Center for Medical Biotechnology, VIB, Ghent, Belgium; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium; VIB Proteomics Core, VIB, Ghent, Belgium.
Ine LentackerGhent Research Group on Nanomedicines, Ghent University, Ghent, Belgium; Cancer Research Institute Ghent (CRIG), Ghent, Belgium.
Bart VandekerckhoveCancer Research Institute Ghent (CRIG), Ghent, Belgium; Department of Diagnostic Sciences, Ghent University, Ghent, Belgium; GMP Unit Cell Therapy, Ghent University Hospital, Ghent, Belgium.
Caroline DemangelInstitut Pasteur, Université Paris Cité, Inserm U1224, Immunobiology and Therapy Unit, Paris, France.
Fabien TheryVIB Center for Medical Biotechnology, VIB, Ghent, Belgium; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium. Electronic address: fabien.thery@vib-ugent.be.
Francis ImpensVIB Center for Medical Biotechnology, VIB, Ghent, Belgium; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium. Electronic address: francis.impens@vib-ugent.be.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mass spectrometry-based immunopeptidomics is a powerful approach for untargeted discovery of peptides presented on MHC molecules, which can guide the selection of vaccine antigens and immunotherapy targets. First-generation immunopeptidomics workflows require processing of hundreds of millions of cells using lengthy, manual procedures. More recent approaches focus on increasing either sensitivity or throughput, but rarely combine both aspects. Here, we describe a semiautomated immunopeptidomics platform that combines high sensitivity with high throughput by implementing highly optimized conditions for isolation of MHC class I and II peptides in a 96-well positive pressure device. Lysis in a small volume of 100 μl allows efficient MHC capture in a 96-well filter plate with optimal pore size for automated washing, elution, and C18 purification steps. Upon analysis of 25% of the eluate from 16 million cells, our workflow identified over 13,500 MHC I and 6000 MHC II peptides on a timsTOF single-cell proteomics mass spectrometer, operating in data-dependent acquisition-parallel accumulation-serial fragmentation mode. Exploring the sensitivity limits of our platform, we identified up to 1000 MHC I peptides, including hundreds of predicted binders, from as few as 20,000 JY cells. Validating the platform's performance for quantitative biological discovery, we report the identification of known and novel bacterial immunopeptides from U937 macrophages infected with Listeria monocytogenes or bacillus Calmette-Guérin. Together, our optimized immunopeptidomics platform enables robust immunopeptide detection from lower-input samples in a high-throughput fashion, enabling its use for biological applications where sample amounts are limiting.

Indexed as

High-Throughput Screening AssaysPeptidesProteomicsHistocompatibility Antigens Class IHistocompatibility Antigens Class IIHumansListeria monocytogenesMass SpectrometryHistocompatibility Antigens Class IHistocompatibility Antigens Class IIPeptidesantigen discoverybacillus Calmette-GuérinBCGimmunopeptidomicsListeria monocytogenesmajor histocompatibility complexMHCtimsTOF

Identifiers

PMID42155729
PMCPMC13284484

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.